CleanCap® Reagent AU
Description
TriLink's patented CleanCap® Reagent AU is designed for the co-transcriptional capping of mRNA to produce an mRNA with naturally occurring Cap 1. CleanCap Reagent AU was specifically designed for self-replicating RNAs based on the genomes of positive sense strand RNA viruses such as Venezuelan equine encephalitis virus (VEEV), Semliki forest virus (SFV), and Sindbis virus (SIN).
The positive sense strand genomes of these viruses start with a 5' AU structure. Cap 1 mRNAs have superior in vivo activity compared to Cap 0 mRNA produced by legacy co-transcriptional capping methods like anti-reverse cap analog (ARCA).
PLEASE NOTE: CleanCap Reagent AU requires an AU initiator. To learn more, please review the Product Insert below.
TriLink's patented CleanCap reagents are available in "Research Use" grade as well as GMP-grade "For Further Processing." GMP product is manufactured in accordance with ISO 9001:2015 and Quality Standards as defined in a GMP Quality Agreement.
To learn more visit: https://www.trilinkbiotech.com/gmp-reagents
Product details
| Catalog No | N-7114 |
| Purity | ≥95% by AX-HPLC |
| Extinction Coefficient | 33 |
| Molecular Formula | C₃₁H₄₂N₁₂O₂₅P₄ (free acid) |
| Molecular Weight | 1106.6 g/mole (free acid) |
| Salt Form | Na+ |
| Concentration | 100 mM |
| Buffer | H₂O |
| Recommended Storage | -20°C or below |
| Application | CRISPR |
| Backbone | 5'-5'-Triphosphate |
| Base Analog(s) | Adenosine |
| Nucleotide Category | Cap analogs |
| Cap Analogs | CleanCap Cap Analogs |
| Shipping Temp | Frozen |
| Sugars | RNA |
Technical documents
- Safety Data Sheet Look-up open_in_new
- CleanCap AU Reagent (N-7114) Product Insert open_in_new
Product FAQs
CleanCap analog is a co-transcriptional small molecule, serving as a trinucleotide primer. It is extended by the RNA polymerase during IVT, enabling high capping efficiency of >95%.
Following the provided the standard protocol, we typically obtain crude RNA yields of 4 to 5 mg/mL from co-transcriptional capping with CleanCap technology.
Yes, please inquire about them from the SKU table provided above or email sales@trilinkbiotech.com.
We have a simple licensing structure for innovators looking to use CleanCap technology in their mRNA drug development. Please find details on the licensing overview page.
Co-transcriptional mRNA capping is a process where mRNA is capped with a cap analog during in vitro transcription as the mRNA is being synthesized. Compared to traditional enzymatic capping methods which occurs post transcriptionally, this process often provides higher efficiency, with fewer steps and less hands-on time.
The CleanCap co-transcriptional capping method caps mRNA with a CleanCap analog during synthesis in a single reaction ("one-pot" process). CleanCap analogs have a naturally occurring cap-1 structure, which is found in higher eukaryotes, reducing immunogenic responses and improving both mRNA stability and functionality.
Please refer to our CleanCap technology's patent fact sheet.
A limited use label license is covered under the terms of sale for research use of CleanCap products and technology.
Please visit our licensing webpage, reach out to your TriLink business development manager, or email licensing@trilinkbiotech.com.
TriLink's commercial licensing framework does not apply running royalties on a per mRNA product sales basis.
They both utilize co-transcriptional capping but differ in the following ways.
Cap structure: ARCA forms a cap-0 structure, which is not recognized as "self" in higher eukaryotes and can trigger unwanted immune responses. CleanCap analogs, on the other hand, form a Cap-1 structure, which is naturally found in higher eukaryotes and thus better controls reactogenicity and improves protein translation.
Transcriptional start site: ARCA's dinucleotide structure (m7GpppG) means that transcription inherently starts with guanosine (G). CleanCap analogs are trinucleotides (m7GpppAmG for mRNA and m7GpppAmU for saRNA) and bind to the +1 and +2 nucleotides downstream of the T7 promoter, incorporating an AG start site in mRNA and an AU start site in saRNA.
GTP competition: ARCA, as a guanosine dimer, competes with free GTP during the in vitro transcription reaction, which can lower both efficiency and yield of capped RNAs. CleanCap analogs, with their AG or AU start site, avoid competition with GTP, eliminating the need for NTP starvation and improving both capping efficiency and RNA yield.
Certificate of analysis
- Certificate of Analysis (CoA) open_in_new
Intellectual property
Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.
CleanCap capping technology
For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license. Patents and patent pending, see trilinkbiotech.com/legal-notices.
Related products
-
CleanCap® Reagent AG N-7113open_in_new
-
CleanCap® Reagent AG (3' OMe) N-7413open_in_new